Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function. 1987

R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri

In a double-blind study the effect of a high dosage of O-(beta-hydroxyethyl)-rutosides (HR) was tested in women taking oral contraceptives and suffering from venous insufficiency of the lower limbs. Ten patients were treated for 28 days with HR (3 g/day) and ten with a placebo. In basal conditions and after therapy, the symptoms of venous disorders and the venous function, by means of strain gauge plethysmography, was evaluated in both groups. The results showed an increase of venous capacitance and a reduction of venous tone in the subjects treated including those without symptoms in the lower limbs. The HR treatment resulted in a significant improvement of the venous function parameters and of the symptoms in lower limbs.

UI MeSH Term Description Entries
D010991 Plethysmography Recording of change in the size of a part as modified by the circulation in it. Plethysmographies
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D003276 Contraceptives, Oral Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both. Low-Dose Oral Contraceptive,Oral Contraceptive,Oral Contraceptives,Oral Contraceptives, Low-Dose,Oral Contraceptives, Phasic,Contraceptive, Low-Dose Oral,Contraceptive, Oral,Contraceptives, Low-Dose Oral,Contraceptives, Phasic Oral,Low Dose Oral Contraceptive,Low-Dose Oral Contraceptives,Oral Contraceptive, Low-Dose,Oral Contraceptives, Low Dose,Phasic Oral Contraceptives
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006896 Hydroxyethylrutoside Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders. 0-beta-Hydroxyethylrutoside,beta-Hydroxyethylrutoside,0 beta Hydroxyethylrutoside,beta Hydroxyethylrutoside
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012431 Rutin A flavonol glycoside found in many plants, including BUCKWHEAT; TOBACCO; FORSYTHIA; HYDRANGEA; VIOLA, etc. It has been used therapeutically to decrease capillary fragility. 3-Rhamnosyl-Glucosyl Quercetin,Quercetin-3-Rutinoside,Rutoside,Quercetin 3 Rutinoside,Quercetin, 3-Rhamnosyl-Glucosyl
D014689 Venous Insufficiency Impaired venous blood flow or venous return (venous stasis), usually caused by inadequate venous valves. Venous insufficiency often occurs in the legs, and is associated with EDEMA and sometimes with VENOUS STASIS ULCERS at the ankle. Insufficiencies, Venous,Insufficiency, Venous,Venous Insufficiencies

Related Publications

R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri
January 1987, Phlebologie,
R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri
May 1972, Deutsches medizinisches Journal,
R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri
September 1986, Minerva medica,
R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri
January 1976, Arzneimittel-Forschung,
R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri
February 1983, Journal of chromatography,
R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri
January 1992, European journal of clinical pharmacology,
R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri
January 1981, Arzneimittel-Forschung,
R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri
September 1971, European journal of clinical pharmacology,
R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri
October 1993, Cancer research,
R Cappelli, and S Pecchi, and V Oberhauser, and S Forconi, and T Di Perri
August 1981, Biochemical pharmacology,
Copied contents to your clipboard!